Lupin has settled all ongoing Hatch-Waxman litigation relating to Venlafaxine extended release capsules with Wyeth. Lupin’s Venlafaxine capsules are the generic version of Wyeth’s Effexor XR capsules. Effexor XR is the world’s best selling antidepressant. According to Wyeth’s financial results, the annual sales of Effexor XR capsules is around USD 3.9 billion for the year 2008 and accounted for 17% of the Wyeth’s net revenues. Under the terms of the settlement, Lupin can launch Venlafaxine capsules on or after
Lupin had earlier filed a Paragraph IV certification to US Patent Nos 6274171, 6403120 and 6419958, citing that these patents were either invalid or had not been infringed, upon which Wyeth filed a lawsuit against Lupin. Earlier to Lupin, Wyeth has also settled patent litigation with two International players (Impax and Teva Pharmaceutical) for the same drug on similar conditions.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: